Loading...
Explore More at wakehealth.edu

Clinical and Translational Science Institute

Keywords
Last Name

Elizabeth Alli, Ph.D.

TitleAssistant Professor
InstitutionWake Forest School of Medicine
DepartmentCancer Biology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Alli E, Ford JM. BRCA1: Beyond double-strand break repair. DNA Repair (Amst). 2015 Aug; 32:165-171. PMID: 25956865.
      View in: PubMed
    2. Alli E, Ford JM. BRCA1: a movement toward cancer prevention. Mol Cell Oncol. 2015 Jul-Sep; 2(3):e979685. PMID: 27308455.
      View in: PubMed
    3. Alli E, Solow-Cordero D, Casey SC, Ford JM. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res. 2014 Nov 01; 74(21):6205-15. PMID: 25217519.
      View in: PubMed
    4. Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat. 2013 Nov; 142(2):389-98. PMID: 24166281.
      View in: PubMed
    5. Alli E, Ford JM. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA Repair (Amst). 2012 May 01; 11(5):522-4. PMID: 22425348.
      View in: PubMed
    6. Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 2011 Jul 19; 11:7. PMID: 21771338.
      View in: PubMed
    7. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010 Oct 15; 70(20):7970-80. PMID: 20798217.
      View in: PubMed
    8. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009 Apr 15; 69(8):3589-96. PMID: 19351835.
      View in: PubMed
    9. Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 2007 May; 71(5):1233-40. PMID: 17272681.
      View in: PubMed
    10. Hait WN, Rubin E, Alli E, Goodin S. Tubulin . Tubulin Targeting Agents. Update on Cancer Therapeutics. 2007; 2(1):1-18.
    11. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007 Feb 15; 26(7):1003-12. PMID: 16909102.
      View in: PubMed
    12. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002 Dec 01; 62(23):6864-9. PMID: 12460900.
      View in: PubMed
    13. Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res. 2002 May; 8(5):1057-64. PMID: 12006519.
      View in: PubMed
    Alli's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _